Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Pramlintide

Symlin / Amylin Analog

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

FDA-approved in 2005 as an amylin analog adjunct to mealtime insulin in type 1 and type 2 diabetes, supported by multiple placebo-controlled RCTs and a systematic review and meta-analysis of 10 trials (pramlintide n=1978, placebo n=1319) showing lower HbA1c, reduced total daily insulin, and modest weight loss. The benefit is real but modest (roughly 0.3 to 0.7 percent additional A1c reduction and a few pounds of weight), so it sits at strong RCT support (grade 4) rather than the overwhelming-consensus grade 5 the entry claimed, and it carries a boxed warning for insulin-induced severe hypoglycemia.

FDA
FDA-approved 2005 (SYMLIN); boxed warning for severe hypoglycemia with insulin
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Boxed warning: insulin-induced severe hypoglycemia, usually within 3 hours of injection; frequent nausea; requires mealtime insulin dose reduction at initiation.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Pramlintide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A synthetic amylin analog, FDA-approved as an adjunct to insulin in type 1 and type 2 diabetes. Reduces post-meal glucose spikes; underutilized despite approval.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • T1D/T2D insulin adjunct
  • Post-meal glucose control

How it works

Pramlintide is a synthetic copy of amylin, a hormone most people have never heard of even though the pancreas releases it alongside insulin at every meal. Amylin is a kind of third hormone of blood sugar control: it tells the liver to ease off releasing glucose after eating, slows how fast food leaves the stomach, and dampens appetite. In type 1 diabetes the cells that make insulin are destroyed, and they made amylin too, so that whole second signal goes missing. Pramlintide, injected at mealtimes alongside insulin, puts it back.

Pramlintide is a synthetic analog of human amylin, the 37-amino-acid hormone co-secreted with insulin by the same pancreatic cells. It differs from natural amylin at three positions, which keep it from clumping the way human amylin does and let it last long enough to use as a drug. It is given by injection before meals, in a separate syringe from insulin, and sold as Symlin.

Type
Synthetic amylin analog
Role
Third glucose hormone
Use
Mealtime insulin adjunct
Weight
Modest loss
Approved
2005
US status
Discontinued (2026)

The First Amylin Drug, Outlived By Its Own Idea

Pramlintide is a clinically sound idea that never became a commercial success, while the idea behind it went on to reshape obesity medicine. As the only amylin-based drug, it restores the meal-time hormone that goes missing alongside insulin in type 1 diabetes, and it does real work: it blunts the post-meal glucose spike, trims the insulin dose, and produces modest weight loss, a useful counter to insulin’s tendency to add weight. But it never caught on widely, because it means another set of injections up to four times a day, the benefit is modest, and combined with insulin it raises the risk of serious low blood sugar, so the insulin dose has to be cut by half when starting. Niche, brand-only, and as of 2026 reported as discontinued in the United States. The twist is that amylin, the hormone it pioneered as a target, is now one of the hottest areas in weight-loss drugs through long-acting analogs like cagrilintide. The drug faded; its mechanism is thriving.

Safety in detail

SYMLIN carries an FDA boxed warning because, when added to mealtime insulin, it is associated with an increased risk of insulin-induced severe hypoglycemia, most often within 3 hours of a dose. The label calls for careful patient selection, initial mealtime insulin dose reduction, and glucose monitoring. Benefit for the approved adjunct-to-insulin use is modest, and the drug remains niche and underutilized.

  • Pramlintide alone does not cause low blood sugar, but combined with mealtime insulin it raises the risk of severe hypoglycemia, especially in type 1 diabetes, usually within about three hours.
  • It carries a boxed warning and requires cutting the mealtime insulin dose by half when starting.
  • Nausea and vomiting are common, reflecting its gastric-emptying and appetite effects.
  • It cannot be mixed with insulin and needs a separate injection, with careful patient selection.
  • It is reported discontinued in the US market as of 2026, so availability is limited.

Children and teenagers

Pramlintide was not a primary pediatric drug; pediatric diabetes is managed mainly with insulin under specialist care. Its hypoglycemia risk with insulin and its mealtime-injection burden made it unsuited to routine pediatric use, and with its US discontinuation it has no meaningful pediatric role.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Pramlintide’s economy was always small: a brand-only diabetes adjunct, Symlin, that never sold widely and is now reported discontinued in the US. The real money in its mechanism has migrated elsewhere, to the long-acting amylin analogs now driving obesity drugs. It is a faded product attached to a thriving pathway.

How we got here

Pramlintide is a synthetic analog of the pancreatic beta-cell hormone amylin (islet amyloid polypeptide, IAPP), engineered by Amylin Pharmaceuticals with substitutions at three amino acid positions to improve solubility and stability. The FDA approved it, marketed as Symlin, in 2005 as an injectable adjunct to mealtime insulin for people with type 1 or type 2 diabetes.

Amylin was recognized as a hormone co-secreted with insulin, a third signal for blood sugar, and a dedicated company developed pramlintide as a stable analog of it. The FDA approved it as Symlin in 2005, an adjunct to insulin, but uptake stayed limited given the injection burden, modest benefit and hypoglycemia risk. In the 2020s the amylin pathway resurged through long-acting analogs like cagrilintide for obesity, and by 2026 pramlintide itself was reported discontinued in the US.

  1. 1980s-1990sAmylin is recognized as insulin’s meal-time partner hormone.
  2. 2005The FDA approves pramlintide as Symlin, an insulin adjunct.
  3. 2000s-2010sUptake stays niche given burden, modest benefit and hypoglycemia risk.
  4. 2020sThe amylin pathway resurges through cagrilintide for obesity.
  5. 2026Pramlintide is reported discontinued in the US market.

The numbers behind the grade

Type
Amylin analog
Role
Third glucose hormone
Use
Insulin adjunct
Weight
Modest loss
Approved
2005
US status
Discontinued

The people taking it

The first and only amylin-analog drug, a mealtime adjunct to insulin that restores the third hormone of glucose control, now faded and reportedly discontinued in the US, even as the amylin pathway it pioneered powers the newest obesity drugs.

Pramlintide was used by people with type 1 diabetes and insulin-using people with type 2 who could not reach glucose targets on insulin alone, a motivated, intensively-managed niche. With its US discontinuation that use is now largely historical, while the broader amylin relevance has shifted to the obesity-drug population.

Was the only approved amylin analog, a mealtime adjunct to insulin in type 1 and type 2 diabetes. Clinically valid but niche, and reported discontinued in the US by 2026, with its pathway now central to obesity drugs.

Set against the alternatives

Against insulin, its partner hormone from the same pancreatic cells, pramlintide replaces the meal-control signal while insulin replaces the glucose-lowering one, so together they more fully restore what type 1 diabetes destroys, and where insulin adds weight, pramlintide trims it. Against cagrilintide, the modern long-acting amylin analog now in blockbuster obesity drugs, pramlintide was the proof of concept and cagrilintide the realized potential, the same pathway with very different commercial fates. And against the GLP-1 drugs, another gut-hormone approach to glucose and weight, the GLP-1 wave largely eclipsed pramlintide’s niche. Its science was right; its moment passed.

What we do not know

  • Whether amylin-based therapy returns to diabetes through the new long-acting analogs.
  • How best to use amylin agonism for weight versus glucose control.
  • Why the original drug underperformed commercially despite sound science.
  • The full obesity potential of the amylin pathway.

What could change

Amylin obesity waveLong-acting amylin analogs like cagrilintide are a leading obesity target.Return to diabetesAmylin agonism may re-enter diabetes care through newer analogs.Easier dosingThe new analogs avoid pramlintide’s multiple daily injections.Pathway over productThe mechanism is thriving even as the original drug fades.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Pramlintide was a prescription diabetes adjunct, not a gray-market or consumer compound, and it is now reported discontinued in the US, so availability is limited. Diabetes management belongs with an endocrinologist, and the amylin concept it pioneered is now delivered by the newer cagrilintide-based drugs rather than something to seek out gray-market.

As a brand-only drug with no generic, pramlintide was relatively expensive, and following its reported US discontinuation availability is now limited.

Pramlintide was a regulated, brand-only pharmaceutical, now of limited availability following US discontinuation. It is not a gray-market peptide.

Brand-only productIt was sold only as a branded pen and vial, with no generic.Limited US supplyIt is reported discontinued in the US as of 2026.Pathway moved onAmylin-analog supply now centers on the new obesity drugs.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Pramlintide.

Nothing outstanding on this one.

Sources

The studies that matter

  • Amylin’s roleestablished

    Amylin is co-secreted with insulin and suppresses post-meal glucagon, slows gastric emptying and curbs appetite, the third hormone of glucose control.

  • Drug designestablished

    Pramlintide differs from amylin at three amino acids, which prevent clumping and extend its half-life enough to use as a medicine.

  • Clinical benefittrials

    Added to mealtime insulin, it improved post-meal glucose, reduced excess glucagon and produced modest weight loss of one to two kilograms.

  • Hypoglycemia riskdocumented

    Combined with insulin it raises the risk of severe low blood sugar, prompting a boxed warning and a fifty-percent cut in mealtime insulin at the start.

  • Approval and decline2005-2026

    Approved in 2005 as the only amylin analog, it remained niche and is reported discontinued in the US by 2026, even as the amylin pathway resurged.